行情

ATNM

ATNM

ACTINIUM PHARMAC
AMEX

实时行情|Nasdaq Last Sale

7.87
-0.26
-3.20%
盘后: 7.87 0 0.00% 19:48 02/25 EST
开盘
8.19
昨收
8.13
最高
8.30
最低
7.79
成交量
45.71万
成交额
--
52周最高
19.47
52周最低
4.710
市值
1.07亿
市盈率(TTM)
-3.0428
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
复发性急性髓细胞白血病药物市场全球潜在增长,份额,需求和主要参与者分析-到2020年至2027年的预测Ameco Research
pune, India, Tue, 23 Feb 2021 02:01:02 / Comserve Inc. / -- Relapsed Acute Myeloid Leukemia Drug market is segmented by Type, and by Application. Players,...
Comserve · 3天前
2021年全球核医学-放射性药物市场规模,包括新兴趋势,行业份额,增长战略,发展中的技术,市场潜力,交易者,区域概述和直至2025年的SWOT分析
Feb 17, 2021 (The Expresswire) -- Global “Nuclear Medicine-Radiopharmaceuticals Market” research report offers qualitative and quantitative insights in...
The Express Wire · 02/18 03:49
复发性急性髓细胞白血病药物市场2021年行业制造商战略分析,份额估计,产品类型,应用,趋势和预测2027
Feb 17, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry.” The global “Relapsed Acute Myeloid...
The Express Wire · 02/17 05:24
核医学-放射性药物市场规模,份额,行业概况,主要参与者分析,增长因素,新兴机会,综合研究,竞争态势以及2021-2025年的行业潜力
The Express Wire · 02/12 06:10
绝对增长率报告:按增长率,收入估计,市场动态,行业趋势和对2027年的预测,复发性急性髓性白血病药物市场规模研究报告2021
Feb 08, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." “Relapsed Acute Myeloid Leukemia Drug...
The Express Wire · 02/08 10:57
2021年阿尔法发射器市场规模全球行业收入,业务增长,需求和应用到2024年的市场研究报告
Feb 02, 2021 (The Expresswire) -- Global Alpha Emitters Market research report provides a Point-by-Point In-Depth analysis of global market size, regional...
The Express Wire · 02/02 06:06
目的和重要性:复发性急性髓细胞白血病药物市场收入,结果分析和预测(2021-2030)-Market.Biz
Jan 28, 2021 (MarketResearch.biz via Comtex) -- The Relapsed Acute Myeloid Leukemia Drug Market research study explains and justifies all tools and...
marketresearch.biz · 01/28 10:26
预计在预测期内(2020年至2025年),阿尔法发射器市场的复合年增长率将达到36.7%的健康水平
New York, Jan 20, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Alpha...
GlobeNewswire · 01/20 12:45
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解ATNM最新的财务预测,通过ATNM每股收益,每股净资产,每股现金流等数据分析ACTINIUM PHARMAC近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ATNM价格均价为38.75,最高价位65.00,最低价为25.00。
EPS
机构持股
总机构数: 42
机构持股: 2,339.65万
持股比例: 172.20%
总股本: 1,358.65万
类型机构数股数
增持
10
554.20万
建仓
5
1,091.19万
减持
6
158.86万
平仓
5
30.64万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.53%
制药与医学研究
-1.34%
高管信息
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer/Chief Accounting Officer
Steve O'Loughlin
Chief Scientific Officer
Dale Ludwig
Other
Mark Berger
Vice President
Robert Daly
Lead Director/Independent Director
C. David Nicholson
Vice President
Steven Price
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Vice President
Vijay Reddy
Independent Director
Richard Steinhart
Vice President
Jehan Rowlands
Independent Director
C.David Nicholson
Independent Director
C. Nicholson
  • 分红
  • 拆股
  • 内部人交易
暂无数据
ATNM 简况
Actinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

微牛提供Actinium Pharmaceuticals Inc(AMEX-ATNM)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ATNM股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ATNM股票基本功能。